Terbinafine transdermal - Crescita Therapeutics

Drug Profile

Terbinafine transdermal - Crescita Therapeutics

Alternative Names: NRI 1002; Penecure; Transcellular antifungal - Crescita

Latest Information Update: 22 Mar 2016

Price : $50

At a glance

  • Originator Nuvo Research
  • Developer Crescita Therapeutics
  • Class Antifungals; Naphthalenes; Small molecules
  • Mechanism of Action Cell membrane modulators; Squalene monooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Onychomycosis

Most Recent Events

  • 17 Aug 2015 Terbinafine transdermal is still in preclinical trials for Onychomycosis in USA (http://www.nuvoresearch.com/products/pipeline/)
  • 11 Aug 2015 Terbinafine transdermal - Nuvo Research is available for licensing as of 11 Aug 2015. http://www.nuvoresearch.com
  • 11 Aug 2015 Nuvo Research has patent protection for terbinafine transdermal in Australia and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top